Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema

Continued treatment over two years with donidalorsen demonstrated sustained reduction in hereditary angioedema attacks and improved quality of life Donidalorsen recently received orphan drug designation in the U.S. Topline Phase 3 results expected in H1 2024 CARLSBAD, Calif. , Nov.